We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
Read MoreHide Full Article
Key Takeaways
ISRG's da Vinci study found significant perioperative gains across 13 benign procedures.
ISRG's da Vinci cut conversion to open surgery by 54% and blood transfusion odds by 13% versus laparoscopy.
ISRG's da Vinci reduced transfusion odds by 69% and 30-day complications by 46% versus open surgery.
Intuitive Surgical (ISRG - Free Report) recently announced the publication of a large systematic review and meta-analysis in the peer-reviewed Annals of Surgery Open, evaluating outcomes from more than 14 million procedures across 13 common benign conditions. The study found that da Vinci robotic-assisted surgery was associated with statistically significant improvements in several perioperative outcomes compared with laparoscopic and open surgery.
The study strengthens Intuitive Surgical's clinical evidence base at a time when the company is focused on expanding da Vinci adoption in high-volume benign procedures globally. The findings also align with management's broader strategy of driving procedure growth through greater clinical validation, cost-focused initiatives such as the upcoming extended-use instrument program and continued investment in the da Vinci ecosystem, which together could support long-term utilization and recurring revenue growth.
Likely Trend of ISRG Stock Following the News
Following the announcement on Sept. 8, shares of ISRG have gained approximately 8% through yesterday’s trading. Year to date, shares of the company have lost 33.3% compared with the industry’s 10.8% decline. However, the S&P 500 has risen 11.4% in the same timeframe.
The newly published large-scale meta-analysis is likely to strengthen Intuitive Surgical's long-term growth prospects by reinforcing the clinical value proposition of its da Vinci platform across high-volume benign procedures, a key area of expansion highlighted by management. Stronger evidence demonstrating improved patient outcomes, shorter hospital stays and faster recovery can support broader surgeon adoption, favorable hospital purchasing decisions and higher procedure volumes.
ISRG currently has a market capitalization of $7.2 million.
Image Source: Zacks Investment Research
More on the Study Findings
The study compared ISRG's da Vinci robotic-assisted surgery with both laparoscopic and open surgery across 13 benign procedures spanning gynecology, general surgery, bariatric surgery, urology and hernia repair. Compared with laparoscopic surgery, da Vinci procedures were associated with a 54% lower likelihood of conversion to open surgery and 13% lower odds of requiring a blood transfusion. Patients also experienced shorter hospital stays by roughly four hours, returned to work about two days earlier, reported lower postoperative pain and required less pain medication, although average operative time was approximately 24 minutes longer.
The benefits were even more pronounced when compared with open surgery. The analysis found a 69% reduction in the odds of blood transfusions, a 46% decline in 30-day postoperative complications and a 60% lower risk of surgical site infections. Patients undergoing da Vinci procedures also had hospital stays that were approximately two days shorter, returned to work nearly five days sooner and showed lower rates of intraoperative complications, readmissions, reoperations and 30-day mortality. The findings were based on 13 randomized controlled trials, 21 prospective cohort studies, 101 database studies and 231 retrospective cohort studies, providing broad evidence across diverse clinical settings.
da Vinci 5 Continues to Gain Momentum
Intuitive Surgical's second-quarter results highlighted continued strong momentum for the da Vinci 5 platform. The company placed 246 da Vinci 5 systems during the quarter, including 114 dual-console systems, bringing the installed base to more than 1,700 systems used by over 15,000 surgeons since launch. Management also noted that the platform's higher utilization, combined with ongoing customer upgrades, continued to support capital demand, particularly in the United States.
The company is further strengthening the platform through a phased rollout of more than 100 planned software and workflow enhancements, with several innovations already submitted for FDA 510(k) clearance. These upgrades are designed to improve telepresence, simulation-based training, care team efficiency and surgical precision, reinforcing management's strategy of expanding da Vinci 5's clinical capabilities while driving long-term procedure growth and ecosystem adoption. These upgrades along with a strong clinical validation should continue to boost Da Vinci 5 adoption going forward..
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global surgical robots market size is projected to grow from $17.2 billion in 2026 to $45.6 billion by 2033, at a CAGR of 14.9%.
The industry’s growth is driven by the rising adoption of robotic-assisted minimally invasive procedures, the increasing demand for surgical precision and the growing use of advanced robotic instruments and accessories across hospitals and surgical centers.
Other News
ISRG recently announced it will expand its manufacturing presence in Asia Pacific with a new facility in Penang, Malaysia, as the company looks to strengthen its ability to meet the rising demand for robotic-assisted surgery in the region. ISRG has entered into a lease agreement with Penang Development Corporation for a 316,000-square-foot manufacturing facility at Bandar Cassia Technology Park.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
ISRG's da Vinci Study Shows Better Outcomes Across 13 Common Conditions
Key Takeaways
Intuitive Surgical (ISRG - Free Report) recently announced the publication of a large systematic review and meta-analysis in the peer-reviewed Annals of Surgery Open, evaluating outcomes from more than 14 million procedures across 13 common benign conditions. The study found that da Vinci robotic-assisted surgery was associated with statistically significant improvements in several perioperative outcomes compared with laparoscopic and open surgery.
The study strengthens Intuitive Surgical's clinical evidence base at a time when the company is focused on expanding da Vinci adoption in high-volume benign procedures globally. The findings also align with management's broader strategy of driving procedure growth through greater clinical validation, cost-focused initiatives such as the upcoming extended-use instrument program and continued investment in the da Vinci ecosystem, which together could support long-term utilization and recurring revenue growth.
Likely Trend of ISRG Stock Following the News
Following the announcement on Sept. 8, shares of ISRG have gained approximately 8% through yesterday’s trading. Year to date, shares of the company have lost 33.3% compared with the industry’s 10.8% decline. However, the S&P 500 has risen 11.4% in the same timeframe.
The newly published large-scale meta-analysis is likely to strengthen Intuitive Surgical's long-term growth prospects by reinforcing the clinical value proposition of its da Vinci platform across high-volume benign procedures, a key area of expansion highlighted by management. Stronger evidence demonstrating improved patient outcomes, shorter hospital stays and faster recovery can support broader surgeon adoption, favorable hospital purchasing decisions and higher procedure volumes.
ISRG currently has a market capitalization of $7.2 million.
Image Source: Zacks Investment Research
More on the Study Findings
The study compared ISRG's da Vinci robotic-assisted surgery with both laparoscopic and open surgery across 13 benign procedures spanning gynecology, general surgery, bariatric surgery, urology and hernia repair. Compared with laparoscopic surgery, da Vinci procedures were associated with a 54% lower likelihood of conversion to open surgery and 13% lower odds of requiring a blood transfusion. Patients also experienced shorter hospital stays by roughly four hours, returned to work about two days earlier, reported lower postoperative pain and required less pain medication, although average operative time was approximately 24 minutes longer.
The benefits were even more pronounced when compared with open surgery. The analysis found a 69% reduction in the odds of blood transfusions, a 46% decline in 30-day postoperative complications and a 60% lower risk of surgical site infections. Patients undergoing da Vinci procedures also had hospital stays that were approximately two days shorter, returned to work nearly five days sooner and showed lower rates of intraoperative complications, readmissions, reoperations and 30-day mortality. The findings were based on 13 randomized controlled trials, 21 prospective cohort studies, 101 database studies and 231 retrospective cohort studies, providing broad evidence across diverse clinical settings.
da Vinci 5 Continues to Gain Momentum
Intuitive Surgical's second-quarter results highlighted continued strong momentum for the da Vinci 5 platform. The company placed 246 da Vinci 5 systems during the quarter, including 114 dual-console systems, bringing the installed base to more than 1,700 systems used by over 15,000 surgeons since launch. Management also noted that the platform's higher utilization, combined with ongoing customer upgrades, continued to support capital demand, particularly in the United States.
The company is further strengthening the platform through a phased rollout of more than 100 planned software and workflow enhancements, with several innovations already submitted for FDA 510(k) clearance. These upgrades are designed to improve telepresence, simulation-based training, care team efficiency and surgical precision, reinforcing management's strategy of expanding da Vinci 5's clinical capabilities while driving long-term procedure growth and ecosystem adoption. These upgrades along with a strong clinical validation should continue to boost Da Vinci 5 adoption going forward..
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global surgical robots market size is projected to grow from $17.2 billion in 2026 to $45.6 billion by 2033, at a CAGR of 14.9%.
The industry’s growth is driven by the rising adoption of robotic-assisted minimally invasive procedures, the increasing demand for surgical precision and the growing use of advanced robotic instruments and accessories across hospitals and surgical centers.
Other News
ISRG recently announced it will expand its manufacturing presence in Asia Pacific with a new facility in Penang, Malaysia, as the company looks to strengthen its ability to meet the rising demand for robotic-assisted surgery in the region. ISRG has entered into a lease agreement with Penang Development Corporation for a 316,000-square-foot manufacturing facility at Bandar Cassia Technology Park.
Intuitive Surgical, Inc. Price
Intuitive Surgical, Inc. price | Intuitive Surgical, Inc. Quote
ISRG’s Zacks Rank & Key Picks
Currently, ISRG has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.